Company profile

  • Committed to Life-Threatening Infectious Diseases
  • Strong, experienced team of scientists
  • Innovative pipeline
  • Track-record of success


Backed by the majority investors, founders and previous owners of Hexal, Drs. Strüngmann, AiCuris was founded in March 2006 as a spin-off of the anti-infectives division of Bayer Health Care, a business unit with a long history of successful anti-infective drug development.
Since then, AiCuris has become a highly focused pharmaceutical company for the discovery, research, and development of novel antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.


AiCuris is led by an experienced management team. At the company’s heart is a group of scientists with broad international experience in drug discovery and development, and know-how gained at both large and small pharmaceutical companies. The team has core expertise in pharmacology, microbiology, virology, pharmacokinetics, medicinal chemistry and clinical development.


With a broad portfolio of anti-infective drugs in specialist indications having profound medical need, AiCuris addresses one of the largest pharmaceutical markets with strong growth potential.
Nearly all AiCuris’ drugs stem from novel chemical classes and most have novel modes of action, making AiCuris’ compounds resistance-breaking by design.

AiCuris now has multiple projects in pre-clinical and clinical development addressing medical needs. The most advanced compound is letermovir (PrevymisTM) which is approved for prophylaxis of CMV reactivation and disease in CMV-seropositive hematopoietic stem cell transplant recipients. A Phase 3 trial in solid organ transplant recipients is ongoing. AIC316 (pritelivir), a helicase-primase inhibitor, being developed to treat herpes simplex virus Type 1 (HSV-1) and Type 2 (HSV-2) infections completed Phase 2 testing in labial herpes and an additional Phase 2 trial in acyclovir resistant infections is ongoing. Two more clinical stage compounds against HBV and bacterial infections are currently in phase 1 testing.

Additional research projects in virology and bacteriology sustain a continuous and balanced pipeline of innovative drug candidates

AiCuris has proven its ability to develop its portfolio rapidly and effectively and is actively pursuing the discovery of novel therapies for infectious diseases with high unmet medical need..


AiCuris’ head office and research laboratories are located at the Pharma- and Chemistry Park in Wuppertal, Germany, where the company occupies 3.000 square meters of purpose built biology and pharmacokinetics facilities for the discovery and development of novel anti-infective agents with a current staff of over 50 employees.